Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
News about Atara Biotherapeutics, Inc. (NASDAQ: ATRA) centers on its development of allogeneic T-cell immunotherapies and the regulatory and business milestones associated with its Epstein-Barr virus (EBV)-specific platform. Atara describes itself as a leader in T-cell immunotherapy, focused on off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, with headquarters in Southern California. Much of the company’s recent news flow has highlighted progress and challenges around tabelecleucel (tab-cel or EBVALLO), its EBV-specific T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Investors following ATRA news can expect updates on FDA interactions, including Biologics License Application (BLA) submissions, Priority Review status, Prescription Drug User Fee Act (PDUFA) target action dates, and Complete Response Letters. Releases have detailed how Atara and its partner Pierre Fabre Laboratories addressed Good Manufacturing Practice (GMP) observations, transferred the tabelecleucel IND and BLA, and responded to evolving FDA positions on the adequacy of the pivotal ALLELE study for accelerated approval.
Company news also covers financial results and corporate restructuring, such as quarterly earnings releases, changes in research and development and general and administrative expenses, workforce reductions, lease amendments, and the impact of tabelecleucel-related milestone payments and commercialization revenue. In addition, Atara has issued updates on its strategic alternatives review, describing potential transactions it may consider to maximize shareholder value.
For readers tracking ATRA, this news stream provides insight into Atara’s clinical and regulatory trajectory, its partnership with Pierre Fabre Laboratories on tabelecleucel/EBVALLO, and the company’s evolving cost structure and strategic direction. Regularly reviewing these updates can help contextualize movements in ATRA stock and developments in the EBV-focused cell therapy space.
Atara Biotherapeutics (ATRA) has reported its Q2 2022 financial results, achieving cash reserves of $331.3 million, an increase from $301.8 million in Q1 2022. The company plans to reduce its annual cash burn by over 20%, extending its cash runway into Q1 2024. Positive developments include FDA's recommended pathway for tab-cel's BLA filing without new trials and completion of the ATA188 Phase 2 EMBOLD study Interim Analysis. However, the termination of the Bayer collaboration will significantly reduce future revenues.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) has granted 82,756 restricted stock units and stock options for 98,701 shares to newly hired employees as part of its 2018 Inducement Plan, effective August 1, 2022. The stock units vest over four years, and the options have a ten-year term with an exercise price of $2.85 per share. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new staff. Atara is focused on T-cell immunotherapy and has multiple programs in clinical development targeting serious diseases.
Atara Biotherapeutics (Nasdaq: ATRA) announced that its CEO, Pascal Touchon, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 9:00 a.m. PDT. The presentation will focus on the company's innovative allogeneic Epstein-Barr virus (EBV) T-cell platform aimed at treating cancer and autoimmune diseases. A live webcast will be available on their website, with an archived replay accessible for 30 days post-event. Atara is advancing several therapies, including tab-cel® for EBV+ PTLD and ATA188 for multiple sclerosis.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its Q2 2022 financial results after the market closes on August 8, 2022. A live conference call and webcast will follow at 4:30 p.m. EDT to discuss results and corporate updates. The company is advancing T-cell immunotherapy using its allogeneic Epstein-Barr virus (EBV) platform, with lead programs in Phase 3 development targeting conditions like EBV+ PTLD and multiple sclerosis. Atara aims to provide off-the-shelf therapies for patients with high unmet medical needs.
Atara Biotherapeutics has announced that its Independent Data and Safety Monitoring Committee (IDSMC) recommended continuing the ATA188 Phase 2 study without adjusting the sample size. The IDSMC did not identify any safety concerns during its evaluation, focusing on the expanded disability status scale (EDSS) and biomarker data. The company achieved its target enrollment of 80 patients and anticipates sharing finalized results in October 2023.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced it will release results from the ATA188 Phase 2 EMBOLD Study Interim Analysis on July 12, 2022, after market close. The study focuses on tackling EBV antigens for potential multiple sclerosis therapy. Following the press release, a live conference call and webcast will occur at 5:00 p.m. EDT. Atara is recognized for its advancements in T-cell immunotherapy, with ongoing clinical programs targeting serious diseases, including solid tumors and autoimmune disorders.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the grant of 31,515 restricted stock units and stock options for 15,227 shares to newly hired employees as part of their 2018 Inducement Plan. The awards were approved by Atara's Compensation Committee and are designed to attract talent under Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with a 25% initial vest on the first anniversary. The stock options have a ten-year term and an exercise price of $8.30 per share, reflecting the stock's closing price on the grant date of July 1, 2022.
Atara Biotherapeutics announced promising results from its Expanded Access Program (EAP) for tabelecleucel (tab-cel) in treating EBV+ PTLD, reporting a 60% overall response rate in patients. Data from 16 treated patients revealed 6 complete and 3 partial responses, with most responses occurring after the first treatment cycle. The company has completed all pre-approval inspections necessary for its EU Marketing Authorization Application, anticipating approval by Q4 2022. These milestones highlight Atara's advancement in T-cell immunotherapy targeting serious diseases.
Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 126,928 restricted stock units and stock options for newly hired employees, totaling 186,378 shares. These awards were approved by the Compensation Committee and are part of Atara's 2018 Inducement Plan, effective June 1, 2022. The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price of $4.83 per share. This action complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent while supporting the company’s growth in T-cell immunotherapy.
Atara Biotherapeutics (NASDAQ: ATRA) announced that Bayer intends to terminate their exclusive worldwide licensing agreement for next-gen mesothelin-directed CAR T-cell therapies, including ATA3271 and ATA2271, aimed at high mesothelin-expressing tumors. This follows Bayer's strategic review prioritizing its pipeline. Atara will regain rights to continue clinical development and commercialization of the therapies and will proceed with ongoing studies, including a Phase 1 trial for ATA2271, even as patient enrollment is paused temporarily. The company will postpone the IND filing for ATA3271 beyond Q4 2022 while maintaining cash runway guidance into Q4 2023.